Biocon Biologics and Regeneron Settle over Yesafili’s (Biosimilar, Eylea) US Launch
Shots:
- Biocon Biologics & Regeneron have entered into a settlement & license agreement, allowing the US launch of Yesafili, an interchangeable biosimilar version of Eylea (aflibercept) by H2’26
- Yesafili’s FDA approval was supported by analytical, nonclinical & clinical data incl. P-III (INSIGHT) trial assessing Yesafili vs Eylea in DME pts, confirming its similarity in PK, safety, efficacy & immunogenicity
- Additionally, Biocon Biologics reached a settlement in Mar, 2024 with Bayer & Regeneron, allowing Canadian launch of Yesafili by Jul 1, 2025
Ref: Biocon Biologics | Image: Biocon Biologics & Regeneron
Related News:- The US FDA Approves Biocon Biologics’ Jobevne (Biosimilar, Avastin)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Ridhi is an avid secondary researcher who follows trends in the biopharmaceutical and healthcare sectors to curate engaging content for the global audience. She works as a news editor at PharmaShots and loves to read books and explore new destinations.
